Treatment implications of the emerging molecular classification system for melanoma (Q37846978)

24 August 2017

1 reference

title

Treatment implications of the emerging molecular classification system for melanoma (English)

1 reference

24 August 2017

Emanuela Romano

1

1 reference

24 August 2017

Gary K Schwartz

2

1 reference

24 August 2017

Paul B Chapman

3

1 reference

24 August 2017

Jedd D Wolchock

4

1 reference

24 August 2017

Richard D Carvajal

5

1 reference

24 August 2017

23 February 2011

1 reference

Lancet Oncology Commission

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

913-922

1 reference

24 August 2017

9

1 reference

24 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Predicting five-year outcome for patients with cutaneous melanoma in a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

The classification of malignant melanoma and its histologic reporting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Malignant melanoma: a unifying concept

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Cutaneous Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

p53 expression and risk factors for cutaneous melanoma: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Is there more than one road to melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Determinants of BRAF mutations in primary melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Essential role for oncogenic Ras in tumour maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Abstracts of Melanoma 2010 Congress, the 7th International Melanoma Research Congress and the 4th Melanoma & Skin Cancer Centres Meeting. November 4-7, 2010. Sydney, Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

The role of KIT in the management of patients with gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Lack of clinical efficacy of imatinib in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Major response to imatinib mesylate in KIT-mutated melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

GAB2 amplifications refine molecular classification of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Gab2-mediated signaling promotes melanoma metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Treating imatinib-resistant leukemia: the next generation targeted therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Effects of G-protein mutations on skin color

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Oncogenic mutations in GNAQ occur early in uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Mutations in GNA11 in uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970274-6

7 January 2021

10.1016/S1470-2045(10)70274-6

Identifiers

DOI

1 reference

24 August 2017

1 reference